Use of TNF-α in the preparation of drugs to alleviate cisplatin nephrotoxicity and its induced acute kidney injury
By using low-dose TNF-α injection pretreatment, cisplatin-induced nephrotoxicity and acute kidney injury can be alleviated, solving the problem of poor passive protection in existing technologies and achieving effective relief of cisplatin nephrotoxicity and protection of renal function.
Patent Information
- Application Number
- CN202211457752.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-21
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-11-21
Smart Images

Figure CN116672437B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedicine, specifically relating to the use of TNF-α in the preparation of drugs to alleviate cisplatin nephrotoxicity and the acute kidney injury it causes. Background Technology
[0002] Cisplatin is one of the most effective and commonly used anti-tumor drugs in clinical practice, widely used for various solid tumors such as bladder cancer, ovarian cancer, head and neck squamous cell carcinoma, testicular cancer, and non-small cell lung cancer. However, cisplatin chemotherapy often leads to serious adverse reactions, including nephrotoxicity, ototoxicity, neurotoxicity, and vomiting. Among these, cisplatin nephrotoxicity is the most significant factor limiting its use in chemotherapy. Even with protective measures such as hydration therapy, the incidence of cisplatin-induced kidney injury remains high in clinical practice. While the efficacy of cisplatin is directly proportional to the dosage, cisplatin-induced nephrotoxicity is also dose-dependent. Therefore, cisplatin nephrotoxicity limits its clinical dosage and efficacy. Thus, how to reduce cisplatin nephrotoxicity, prevent and alleviate acute kidney injury caused by cisplatin, better exert the anti-tumor effect of cisplatin, and improve the quality of chemotherapy for patients is an urgent problem to be solved in this field.
[0003] Currently, the main preventive measures against cisplatin nephrotoxicity in clinical practice are hydration and diuresis, with serum creatinine and blood urea nitrogen used as monitoring indicators of cisplatin nephrotoxicity. Cisplatin dosage is reduced or the drug is discontinued when renal function changes. However, this approach is relatively passive. Due to the kidney's own reserve and compensatory capacity, serum creatinine and blood urea nitrogen usually do not change when renal function is mildly or in the early stages of damage. When these levels are higher than normal, it indicates that 60-70% of the effective nephrons have been damaged (Wan Ting, Li Lianhong. Research progress on the mechanism of cisplatin nephrotoxicity and its protection [J]. Chinese Journal of Clinical Physicians (Electronic Edition), 2013(14):6623-6625.DOI:10.3969 / cma.j.issn.1674-0785.2013.14.098.). Therefore, adopting more proactive measures to protect the kidneys in advance and prevent cisplatin-induced nephrotoxicity and kidney damage is of greater significance.
[0004] TNF-α, or tumor necrosis factor, is a ligand of the TNF superfamily. It is a pleiotropic cellular molecule that plays a central role in inflammation, apoptosis, and immune system development. TNF-α is secreted by macrophages, monocytes, neutrophils, CD4+ T cells, and NK cells, and belongs to the pro-inflammatory cytokine family. It participates in normal inflammatory and immune responses and can synergistically regulate the production of other cytokines, cell survival, and death to coordinate tissue homeostasis.
[0005] Studies have found an association between cisplatin nephrotoxicity and inflammatory responses. In a mouse model of cisplatin nephrotoxicity, TNF-α expression in the kidneys increased, and the use of TNF-α inhibitors or knockout of the TNF-α gene significantly reduced cisplatin-induced renal insufficiency and histological damage. However, the exact effect of TNF-α on cisplatin nephrotoxicity remains unreported. Summary of the Invention
[0006] The purpose of this invention is to provide a new use for TNF-α.
[0007] This invention provides the use of TNF-α in the preparation of drugs to alleviate kidney damage.
[0008] The kidney injury described is drug-induced kidney injury.
[0009] Furthermore, the aforementioned drug-induced kidney injury is kidney injury induced by antibiotics, nonsteroidal anti-inflammatory drugs, antitumor drugs, traditional Chinese medicines, contrast agents, or diuretics;
[0010] Preferably, the antibiotics include neomycin, kanamycin, gentamicin, penicillin, cephalosporins, and polymyxin;
[0011] The nonsteroidal anti-inflammatory drugs include aspirin, ibuprofen, phenylbutazone, naproxen, indomethacin, piroxicam, and cyclophosphamide;
[0012] The antitumor drugs include cisplatin, methotrexate, streptomycin, carmustine, chlorophenoxycycline, and hexanilide;
[0013] The Chinese medicines included mainly include those containing aristolochic acid and / or its derivatives, such as Guanmutong, Madouling, and Tianxianteng.
[0014] The contrast agent includes an iodine-containing contrast agent; the diuretic includes an osmotic diuretic and furosemide.
[0015] Furthermore, the aforementioned drugs are for relieving cisplatin-induced acute kidney injury.
[0016] Furthermore, the aforementioned drugs are designed to reduce kidney tissue damage.
[0017] The present invention also provides the use of TNF-α in the preparation of drugs to alleviate cisplatin nephrotoxicity.
[0018] Furthermore, the aforementioned drugs are those that lower serum creatinine levels.
[0019] The present invention also provides a drug for relieving kidney damage, which is a formulation prepared with TNF-α as the sole active ingredient and pharmaceutically acceptable excipients.
[0020] Furthermore, the above-mentioned formulation is an injectable preparation; preferably, the pharmaceutically acceptable excipient is a PBS solution.
[0021] Furthermore, each unit of the above-mentioned injection contains 550–770 μg of TNF-α, preferably 660 μg of TNF-α.
[0022] Beneficial effects of the present invention: The present invention is the first to discover that pretreatment with low doses of TNF-α can significantly alleviate the nephrotoxicity of cisplatin and effectively reduce cisplatin-induced kidney damage, which has guiding significance for clinical intervention measures for acute kidney injury or tumor chemotherapy.
[0023] In this invention, "each unit formulation" means: a physical discrete unit suitable for use as a unit dose for human subjects, each unit containing a predetermined amount of active substance calculated to produce the desired therapeutic effect and suitable pharmaceutical excipients.
[0024] Obviously, based on the above description of the present invention, and according to common technical knowledge and conventional methods in the field, various other modifications, substitutions or alterations can be made without departing from the basic technical concept of the present invention.
[0025] The following detailed embodiments further illustrate the above-described content of the present invention. However, this should not be construed as limiting the scope of the present invention to the following examples. All technologies implemented based on the above-described content of the present invention fall within the scope of the present invention. Attached Figure Description
[0026] Figure 1 Pretreatment with TNF-α reduced serum creatinine levels in a cisplatin-induced AKI mouse model.
[0027] Figure 2 TNF-α pretreatment was used to improve cisplatin-induced kidney tissue damage in a mouse model of AKI (n=10). The experiment was independently repeated twice.
[0028] Figure 3 TNF-α pretreatment was used to improve survival in a cisplatin-induced AKI mouse model. The experiment was independently repeated twice (n=10). Detailed Implementation
[0029] The TNF-α used in this invention was purchased from Peprotech, Cat#315-01A, and diluted with PBS for later use. The mice used in this invention were 6-8 week old C57 / BL6 mice purchased from Vital River Pharmaceuticals, and were used in experiments after approximately one week of acclimatization.
[0030] Unless otherwise stated, all other raw materials and equipment used in this invention are known products, obtained by purchasing commercially available products.
[0031] Example 1: Low-dose TNF-α pretreatment alleviates cisplatin nephrotoxicity and its induced acute kidney injury
[0032] 1. Experimental Methods
[0033] Mice were randomly divided into three groups: PBS group, cisplatin group, and TNF-α+cisplatin group, with 10 mice in each group.
[0034] (1) PBS group (NS): PBS solution was injected into mice intraperitoneally, and no acute kidney injury (AKI) modeling was performed in mice.
[0035] (2) Cisplatin group: PBS solution was injected into mice intraperitoneally, and 24 hours later, cisplatin was used to model acute kidney injury (AKI) in mice.
[0036] (3) TNF-α + Cisplatin group (TNF-α + Cis): TNF-α was injected intraperitoneally into mice at a dose of 2 μg / mouse (100 μg / kg). 24 hours later, cisplatin was used to model acute kidney injury (AKI) in mice.
[0037] Specimens were collected 24 hours after modeling, and the progression of AKI was evaluated by serum creatinine and tissue HE staining. The survival status of mice was observed and data were recorded every 6-12 hours.
[0038] AKI modeling method: Cisplatin (Chemlin) was administered intraperitoneally to mice at a dose of 25 mg / kg via a single injection. This method was previously validated: 6-8 week old C57 / BL6 female mice were selected and administered the injection intraperitoneally (25 mg / kg). Specimens (serum and kidney tissue) were collected 24 hours later. Successful AKI modeling was confirmed by HE staining of serum creatinine and kidney tissue, respectively.
[0039] 2. Experimental Results
[0040] like Figure 1 As shown, TNF-α pretreatment significantly reduced serum creatinine levels in cisplatin-induced mouse models, indicating that TNF-α has a significant alleviating effect on cisplatin nephrotoxicity.
[0041] like Figure 2 As shown in the HE staining results, TNF-α pretreatment can significantly improve kidney tissue damage in AKI mouse models and has a protective effect on kidney tissue.
[0042] like Figure 3 As shown, TNF-α pretreatment can also significantly prolong the survival of AKI mouse models.
[0043] The above results indicate that pretreatment with TNF-α can significantly alleviate cisplatin nephrotoxicity and effectively reduce cisplatin-induced kidney injury. The TNF-α dose injected into mice was 100 μg / kg. Based on the average adult body weight, the human dose is only about 660 μg / kg. The dose is low and the safety is high, which can guide clinical intervention measures for acute kidney injury or tumor chemotherapy.
Claims
1. The use of TNF-α in the preparation of drugs to alleviate kidney injury, characterized in that, The kidney injury was cisplatin-induced; the dose of TNF-α was 550–770 μg / kg.
2. The use as described in claim 1, characterized in that, The drug is used to alleviate cisplatin-induced acute kidney injury.
3. The use as described in claim 2, characterized in that, The drug is used to reduce kidney tissue damage.
